Sector
PharmaceuticalsOpen
₹327.5Prev. Close
₹325.9Turnover(Lac.)
₹1,250.59Day's High
₹329.95Day's Low
₹31752 Week's High
₹41552 Week's Low
₹286.6Book Value
₹124.07Face Value
₹2Mkt Cap (₹ Cr.)
2,944.76P/E
27.82EPS
11.7Divi. Yield
0.4628 Aug 2023
12:00 AM
AGM
Announcement Date: 28 Aug, 2023
10 Jul 2024
12:00 AM
Board Meeting
Agenda : Audited Result
1 Sep 2023
12:00 AM
BookCloser
23 May 2023
12:00 AM
Dividend
Dividend Amount: 2.25
Record Date: 19 Sep, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 18.43 | 18.43 | 18.43 | 18.43 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,008.59 | 885.87 | 750.5 | 661.73 |
Net Worth | 1,027.02 | 904.3 | 768.93 | 680.16 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 1,240.3 | 1,105.99 | 967.73 | 1,038.21 |
yoy growth (%) | 12.14 | 14.28 | -6.78 | -5.1 |
Raw materials | -354.06 | -330.42 | -320.17 | -346.03 |
As % of sales | 28.54 | 29.87 | 33.08 | 33.32 |
Employee costs | -272.87 | -255.31 | -231.26 | -220.33 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 131.35 | 28.7 | -9.24 | 48.42 |
Depreciation | -73.12 | -70.81 | -71.56 | -67.7 |
Tax paid | -38.95 | -4.46 | 6.4 | -7.23 |
Working capital | 108.84 | 8.53 | -20.15 | -48.05 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 12.14 | 14.28 | -6.78 | -5.1 |
Op profit growth | 81.26 | 60.8 | -43.11 | -13.9 |
EBIT growth | 179.41 | 386.57 | -84.29 | -26.21 |
Net profit growth | 281.02 | -953.47 | -106.89 | -46.81 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,788.22 | 1,640.05 | 1,503.73 | 1,218.61 | 1,079.98 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,788.22 | 1,640.05 | 1,503.73 | 1,218.61 | 1,079.98 |
Other Operating Income | 29.07 | 28.56 | 37.02 | 22.92 | 26.61 |
Other Income | 21.38 | 2.34 | 2.33 | 3.12 | 2.44 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.35 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.8 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,490 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.55 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,770.9 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Wholetime Director
Suresh G Kare
Managing Director
Aditi Kare Panandikar
Joint Managing Director
Sundeep V Bambolkar
Independent Non Exe. Director
Rajiv Kakodkar
Independent Non Exe. Director
D M Gavaskar
Independent Non Exe. Director
Vasudha V Kamat
Independent Non Exe. Director
Abhijit Y Gore
Non Executive Director
Anand Nadkarni
Additional Director
Ajay Mulgaokar
Additional Director
Satish Shenoy
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Indoco Remedies Ltd
Summary
Indoco Remedies Limited, incorporated as a Public Limited Company in August 23, 1947 is a Mumbai-based pharmaceutical company that focuses on formulations, with some presence in contract manufacturing and research. The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 166 million Company, employs over 6000 people including more than 300 skilled scientists. The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility.Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal. As per AC Nielsen ORG-MARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORG-MARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardio-vascular segments. Its entry into the lif
Read More
What is the Indoco Remedies Ltd share price today?
The Indoco Remedies Ltd shares price on N/A is Rs.₹317.65 today.
What is the Market Cap of Indoco Remedies Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Indoco Remedies Ltd is ₹2928.17 Cr. as of 23 Jul ‘24
What is the PE and PB ratio of Indoco Remedies Ltd?
The PE and PB ratios of Indoco Remedies Ltd is 27.82 and 2.66 as of 23 Jul ‘24
What is the 52 Week High and Low of Indoco Remedies Ltd?
The 52-week high/low is the highest and lowest price at which a Indoco Remedies Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Indoco Remedies Ltd is ₹286.5 and ₹416.95 as of 23 Jul ‘24
What is the CAGR of Indoco Remedies Ltd?
Indoco Remedies Ltd's CAGR for 5 Years at 15.77%, 3 Years at -10.16%, 1 Year at -1.23%, 6 Month at -11.83%, 3 Month at -0.72% and 1 Month at -0.81%.
What is the shareholding pattern of Indoco Remedies Ltd?
The shareholding pattern of Indoco Remedies Ltd is as follows:
Promoters - 58.75 %
Institutions - 20.14 %
Public - 21.07 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
